<Record>
<Term>Fomivirsen</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<SemanticType>Organic Chemical</SemanticType>
<ParentTerm>Antisense Oligonucleotides</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Biological Agent/Antisense Oligonucleotides/Fomivirsen Sodium</ClassificationPath>
<BroaderTerm>Fomivirsen Sodium</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Biological Agent</BroaderTerm>
<BroaderTerm>Antisense Oligonucleotides</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>Fomivirsen Sodium</Synonym>
<Synonym>Fomivirsen sodium</Synonym>
<Synonym>Fomivirsen</Synonym>
<Synonym>ISIS 2922</Synonym>
<Synonym>Vitravene</Synonym>
<Synonym>FOMIVIRSEN SODIUM</Synonym>
<Synonym>Vitravene Preservative Free</Synonym>
<Description>The sodium salt form of fomivirsen, an antisense phosphorothioate oligodeoxynucleotide (ODN) with potent antiviral property. Fomivirsen is a 21-nucleotide ODN complementary to mRNA of the immediate-early region 2 of human cytomegalovirus (CMV). Hybridization of this antisense ODN to CMV mRNA prevents RNA transcription from the immediate-early region 2 gene, thereby inhibiting viral replication. In addition, this agent inhibits adsorption of CMV into host cells via a sequence-independent mechanism. Overall, fomivirsen inhibits viral propagation via inhibiting viral replication and viral uptake by host cells, hence delaying progression of CMV-associated retinitis.</Description>
<Source>FDA Registry</Source>
<Source>NCI Thesaurus</Source>
</Record>
